Felix Woodhead

3.0k total citations · 1 hit paper
25 papers, 684 citations indexed

About

Felix Woodhead is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Felix Woodhead has authored 25 papers receiving a total of 684 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 10 papers in Rheumatology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Felix Woodhead's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (24 papers), Systemic Sclerosis and Related Diseases (7 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Felix Woodhead is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (24 papers), Systemic Sclerosis and Related Diseases (7 papers) and Rheumatoid Arthritis Research and Therapies (6 papers). Felix Woodhead collaborates with scholars based in United Kingdom, United States and Canada. Felix Woodhead's co-authors include Julie Dawson, Clive Kelly, Gouri Koduri, Muhammad K Nisar, Yasmeen Ahmad, N. Sathi, S. Arthanari, A. Young, V. Saravanan and Athol U. Wells and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and Human Molecular Genetics.

In The Last Decade

Felix Woodhead

23 papers receiving 674 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study

2014 377 citations Clive Kelly, V. Saravanan et al. Lara D. Veeken profile →

Peers

Countries citing papers authored by Felix Woodhead

Since Specialization

Citations

This map shows the geographic impact of Felix Woodhead's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Woodhead with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Woodhead more than expected).

Fields of papers citing papers by Felix Woodhead

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Woodhead. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Woodhead. The network helps show where Felix Woodhead may publish in the future.

Co-authorship network of co-authors of Felix Woodhead

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Woodhead. A scholar is included among the top collaborators of Felix Woodhead based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Woodhead. Felix Woodhead is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhaled Nintedanib (AP02) for the Treatment of IPF: Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses to Healthy Subjects and IPF Patients 2025 ·American Journal of Respiratory and Critical Care Medicine ·Miriam Palacios‐Callender, (unknown), (unknown), Deepthi Nair, Felix Woodhead	0
2	Survival differences in rheumatoid arthritis interstitial lung disease and idiopathic pulmonary fibrosis may be explained by delays in presentation: results from multivariate analysis in a monocentric UK study 2023 ·Rheumatology International ·Shirish Dubey, Felix Woodhead	1
3	Nebulised pirfenidone in non-idiopathic pulmonary fibrosis (IPF) progressive pulmonary fibrosis (PPF): first look at FVC data 2023 ·Alex West, Alexandra Lawrence, Hao Bao, Deepthi Nair, C. Thompson, Felix Woodhead	0
4	A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SAFETY, TOLERABILITY, AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH RHEUMATOID ARTHRITIS INTERSTITIAL LUNG DISEASE 2022 ·CHEST Journal ·Joshua J. Solomon, Felix Woodhead, (unknown), (unknown), (unknown), (unknown), (unknown), Rie Maurer, (unknown), (unknown), Hilary J. Goldberg, (unknown)	7
5	Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study 2021 ·BMJ Open Respiratory Research ·Shaney Barratt, Andrew Creamer, Huzaifa Adamali, Anna Duckworth, (unknown), (unknown), (unknown), (unknown), (unknown), Bibek Gooptu, Michael Gibbons, Felix Woodhead, Chris J. Scotton	7
6	Rheumatoid arthritis related interstitial lung disease – improving outcomes over 25 years: a large multicentre UK study 2020 ·Lara D. Veeken ·Clive Kelly, Mohamed Nisar, (unknown), (unknown), Felix Woodhead, (unknown), David Middleton, Owen Dempsey, (unknown), Neil Basu, Julie Dawson, (unknown), Yasmin Ahmad, (unknown), (unknown), (unknown), Gouri Koduri, Adam Young	54
7	The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease 2019 ·Advances in Therapy ·(unknown), Joshua J. Solomon, Sonye K. Danoff, Hilary J. Goldberg, Felix Woodhead, Martin Kolb, Daniel C. Chambers, (unknown), (unknown), (unknown), Shelley Hurwitz, Elizabeth Peters, Paul F. Dellaripa, Iván O. Rosas	45
8	208 Progression in ILD: comparison of rheumatological and non-rheumatological ILD 2019 ·Lara D. Veeken ·Shirish Dubey, Felix Woodhead	1
9	092 The Effect of Steroids, Azathioprine and Mycophenolate on the Risk of Death in Rheumatoid Lung Disease 2016 ·Lara D. Veeken ·Clive Kelly, Adam Young, Yasmeen Ahmad, Julie Dawson, Sara Carty, (unknown), Felix Woodhead	5
10	063 Survival in Rheumatoid Lung Disease is Longer in Patients Treated with Rituximab than in those Receiving Anti-Tumour Necrosis Factor Therapy 2016 ·Lara D. Veeken ·(unknown), Sara Carty, Julie Dawson, Felix Woodhead, Adam Young, Clive Kelly	4
11	068. Cyclophosphamide in the Treatment of Severe Interstitial Lung Disease in Patients with Rheumatoid Arthritis 2015 ·Lara D. Veeken ·(unknown), Judith R. Gordon, (unknown), David Middleton, (unknown), Adam Young, Julie Dawson, Subha Arthanari, Felix Woodhead, (unknown), (unknown), (unknown), Gouri Koduri, Clive Kelly	1
12	Comparison of physiological impairment in ILD patients with and without diagnostic IPF features 2014 ·European Respiratory Journal ·(unknown), (unknown), (unknown), (unknown), Felix Woodhead, Emma Helm, Rhian Hughes, David Parr	1
13	Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study breakdown → 2014 ·Lara D. Veeken ·Clive Kelly, V. Saravanan, Muhammad K Nisar, S. Arthanari, Felix Woodhead, (unknown), Julie Dawson, N. Sathi, Yasmeen Ahmad, Gouri Koduri, A. Young, (unknown)	377
14	SAT0130 Rheumatoid Arthritis Related Interstitial Lung Disease – is There an Association between Disease Modifying anti Rheumatic Drugs and Survival? 2014 ·Annals of the Rheumatic Diseases ·Matthew A. Brown, Clive Kelly, Muhammad K Nisar, S. Arthanari, Felix Woodhead, (unknown), David Middleton, Owen Dempsey, Julie Dawson, N. Sathi, Yasmin Ahmad, Gouri Koduri, Adam Young, Elena Nikiphorou	1
15	OP0254 Association between Steroid Therapy and Survival in Patients with Rheumatoid Arthritis Interstitial Lung Disease 2014 ·Annals of the Rheumatic Diseases ·(unknown), Muhammad K Nisar, S. Arthanari, Felix Woodhead, (unknown), David Middleton, Owen Dempsey, (unknown), N. Sathi, Yasmin Ahmad, Gouri Koduri, Elena Nikiphorou, Adam Young, Clive Kelly	2
16	O36. Rheumatoid-Arthritis-Related Interstitial Lung Disease: Association Between Biologic Therapy and Survival 2014 ·Lara D. Veeken ·(unknown), Clive Kelly, Mohamed Nisar, Subha Arthanari, Felix Woodhead, (unknown), David Middleton, Owen Dempsey, Julie Dawson, (unknown), Yasmeen Ahmad, Gouri Koduri, A. Young	4
17	Assessment of the potential utility of alveolar volume (VA) as a surrogate for total lung capacity (TLC) 2014 ·(unknown), James Stockley, (unknown), (unknown), Felix Woodhead, Rhian Hughes, (unknown), (unknown), Robert A. Stockley, David Parr	2
18	FRI0114 Rheumatoid arthritis related interstitial lung disease – relevance of lung function tests and high resolution computed tomography in a large multi centre series 2013 ·Annals of the Rheumatic Diseases ·Carol Kelly, Eva K.F. Chan, Muhammad K Nisar, S. Arthanari, Felix Woodhead, Julie Dawson, N. Sathi, Yasmin Ahmad	1
19	Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups 2010 ·Human Molecular Genetics ·Hiroe Sato, Felix Woodhead, Tariq Ahmad, Jan C. Grutters, Paolo Spagnolo, Jules M.M. van den Bosch, Lisa A. Maier, Lee S. Newman, Sonoko Nagai, Takateru Izumi, Athol U. Wells, Roland M. du Bois, Kenneth I. Welsh	99
20	Pulmonary Complications of Connective Tissue Diseases 2008 ·Clinics in Chest Medicine ·Felix Woodhead, Athol U. Wells, Sujal R. Desai	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact